{
    "nct_id": "NCT06588478",
    "official_title": "A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor",
    "inclusion_criteria": "* Have confirmed diagnosis of CLL/SLL as defined by these iwCLL 2018 criteria.\n* Have received prior CLL/SLL treatment\n* Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL\n* Have received a covalent BTK inhibitor\n* Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy\n* Capable of swallowing oral study medication.\n* Have an Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0 to 2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have received prior treatment with a BTK degrader and a noncovalent BTK inhibitor\n* Have a history of greater than or equal to (>=) Grade 3 bleeding due to treatment with a BTK inhibitor\n* Have known or suspected Richter's transformation\n* Have known or suspected history of central nervous system involvement by CLL/SLL\n* Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:\n\n  * nonmelanoma skin cancer or lentigo maligna melanoma\n  * cervical carcinoma in situ\n  * localized prostate cancer undergoing active surveillance, and\n  * localized (for example, lymph node negative) breast cancer with no evidence of active disease present for more than 3 years. Individual may be receiving adjuvant hormonal therapy",
    "miscellaneous_criteria": ""
}